Published in Circ Res on October 27, 2000
Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest (2005) 5.48
miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med (2010) 3.50
Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A (2002) 3.27
Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest (2004) 3.09
Impaired cardiac hypertrophic response in Calcineurin Abeta -deficient mice. Proc Natl Acad Sci U S A (2002) 2.56
Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol (2002) 2.30
The cardiomyocyte circadian clock: emerging roles in health and disease. Circ Res (2010) 1.94
Critical role for stromal interaction molecule 1 in cardiac hypertrophy. Circulation (2011) 1.91
Inositol 1, 4, 5-trisphosphate receptors and human left ventricular myocytes. Circulation (2013) 1.73
Impaired contractile function and calcium handling in hearts of cardiac-specific calcineurin b1-deficient mice. Am J Physiol Heart Circ Physiol (2009) 1.56
Early cardiac hypertrophy in mice with impaired calmodulin regulation of cardiac muscle Ca release channel. J Clin Invest (2007) 1.53
Calcineurin and cardiac hypertrophy: where have we been? Where are we going? J Physiol (2002) 1.50
Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol Cell Biol (2003) 1.45
Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res (2012) 1.35
Ca2+ oscillation frequency decoding in cardiac cell hypertrophy: role of calcineurin/NFAT as Ca2+ signal integrators. Proc Natl Acad Sci U S A (2008) 1.34
miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. J Biol Chem (2010) 1.34
CaMKII negatively regulates calcineurin-NFAT signaling in cardiac myocytes. Circ Res (2009) 1.33
Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation. Circ Res (2008) 1.26
Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. J Am Coll Cardiol (2001) 1.17
Genome-wide association study identifies single-nucleotide polymorphism in KCNB1 associated with left ventricular mass in humans: the HyperGEN Study. BMC Med Genet (2009) 1.17
Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy. Nat Rev Cardiol (2012) 1.15
Cholecystokinin activates pancreatic calcineurin-NFAT signaling in vitro and in vivo. Mol Biol Cell (2007) 1.14
Pacing-induced calcineurin activation controls cardiac Ca2+ signalling and gene expression. J Physiol (2003) 1.12
Signaling pathways and late-onset gene induction associated with renal mesangial cell hypertrophy. EMBO J (2002) 1.11
Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice. J Physiol (2009) 1.08
Regulation of calcineurin through transcriptional induction of the calcineurin A beta promoter in vitro and in vivo. Mol Cell Biol (2005) 1.06
Ryanodine receptor leak mediated by caspase-8 activation leads to left ventricular injury after myocardial ischemia-reperfusion. Proc Natl Acad Sci U S A (2011) 1.05
The mAKAPbeta scaffold regulates cardiac myocyte hypertrophy via recruitment of activated calcineurin. J Mol Cell Cardiol (2009) 1.05
Increased susceptibility to isoproterenol-induced cardiac hypertrophy and impaired weight gain in mice lacking the histidine-rich calcium-binding protein. Mol Cell Biol (2006) 1.02
Mechanotransduction in cardiac hypertrophy and failure. Circ Res (2015) 1.01
Genetic ablation of ryanodine receptor 2 phosphorylation at Ser-2808 aggravates Ca(2+)-dependent cardiomyopathy by exacerbating diastolic Ca2+ release. J Physiol (2014) 0.99
Activation of a nuclear factor of activated T-lymphocyte-3 (NFAT3) by oxidative stress in carboplatin-mediated renal apoptosis. Br J Pharmacol (2010) 0.96
Post-translational protein modification by O-linked N-acetyl-glucosamine: its role in mediating the adverse effects of diabetes on the heart. Life Sci (2012) 0.92
Selective deletion of long but not short Cypher isoforms leads to late-onset dilated cardiomyopathy. Hum Mol Genet (2011) 0.92
CXCR4 gene transfer prevents pressure overload induced heart failure. J Mol Cell Cardiol (2012) 0.91
CaMKII regulation of cardiac ryanodine receptors and inositol triphosphate receptors. Front Pharmacol (2014) 0.89
Curcumin prevents cardiac remodeling secondary to chronic renal failure through deactivation of hypertrophic signaling in rats. Am J Physiol Heart Circ Physiol (2010) 0.87
New frontiers in heart hypertrophy during pregnancy. Am J Cardiovasc Dis (2012) 0.86
Gene network analysis during early infection of human coronary artery smooth muscle cells by Trypanosoma cruzi and Its gp83 ligand. Chem Biodivers (2010) 0.85
MAFbx/Atrogin-1 is required for atrophic remodeling of the unloaded heart. J Mol Cell Cardiol (2014) 0.83
Prevention of isoproterenol-induced cardiac hypertrophy by eugenol, an antioxidant. Indian J Clin Biochem (2006) 0.82
The other side of cardiac Ca(2+) signaling: transcriptional control. Front Physiol (2012) 0.80
Dominant negative Ras attenuates pathological ventricular remodeling in pressure overload cardiac hypertrophy. Biochim Biophys Acta (2015) 0.77
Imatinib activates pathological hypertrophy by altering myocyte calcium regulation. Clin Transl Sci (2014) 0.77
Selective clinical and immune response of the oligoclonal autoreactive T cells in Omenn patients after cyclosporin A treatment. Clin Exp Immunol (2012) 0.75
Counteracting Protein Kinase Activity in the Heart: The Multiple Roles of Protein Phosphatases. Front Pharmacol (2015) 0.75
High throughput phenotyping of left and right ventricular cardiomyopathy in calcineurin transgene mice. Int J Cardiovasc Imaging (2015) 0.75